This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hauser, R. G. Search for Related Content PubMed PubMed Citation Articles by Hauser, R. G.

CLINICAL RESEARCH: HEART RHYTHM DISORDER: VIEWPOINT

The Growing Mismatch Between Patient Longevity and the Service Life of Implantable Cardioverter-Defibrillators

Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.

Manuscript received January 17, 2005; revised manuscript received February 22, 2005, accepted February 28, 2005.

^_* Reprint requests and correspondence: Dr. Robert G. Hauser, Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 300, Minneapolis, Minnesota 55407. (Email: rhauser747{at}aol.com).

Implantable cardioverter-defibrillators (ICDs) are lifesaving devices. Over 100,000 patients received ICDs in 2004 at a cost of $2 billion for the pulse generators alone. Because of expanded indications and coverage by Medicare, the number of ICD implantations and replacements is expected to increase dramatically during the next decade. The average ICD patient at our institution now lives nearly 10 years after the procedure. However, the service life of pulse generators has decreased from 4.7 ± 1 year for single-chamber units to 4.0 ± 1 year for dual-chamber devices. This mismatch between patient longevity and the service life of ICDs poses a significant clinical and economic burden that must be addressed. One near-term solution is for manufacturers to provide devices with larger batteries so that most patients can have an ICD pulse generator that lasts a lifetime. For the long-term, more robust or renewable energy sources are needed.

Abbreviations and Acronyms   CRT = cardiac resynchronization therapy   ICD = implantable cardioverter-defibrillator   QALY = quality-adjusted life year

This article has been cited by other articles:

				M. Biffi, M. Ziacchi, M. Bertini, D. Sangiorgi, D. Corsini, C. Martignani, I. Diemberger, and G. Boriani Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems Europace, November 1, 2008; 10(11): 1288 - 1295. [Abstract] [Full Text] [PDF]

				D. B. Mark, C. L. Nelson, K. J. Anstrom, S. M. Al-Khatib, A. A. Tsiatis, P. A. Cowper, N. E. Clapp-Channing, L. Davidson-Ray, J. E. Poole, G. Johnson, et al. Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Circulation, July 11, 2006; 114(2): 135 - 142. [Abstract] [Full Text] [PDF]

				G. D. Sanders, M. A. Hlatky, and D. K. Owens Cost-Effectiveness of Implantable Cardioverter-Defibrillators N. Engl. J. Med., October 6, 2005; 353(14): 1471 - 1480. [Abstract] [Full Text] [PDF]

				R. G. Hauser and B. J. Maron Lessons From the Failure and Recall of an Implantable Cardioverter-Defibrillator Circulation, September 27, 2005; 112(13): 2040 - 2042. [Full Text] [PDF]